You are here

Article Text

Article menu
Download PDFPDF
Letters
Serum β2 microglobulin correlates with the new ESSDAI in patients with Sjögren's syndrome
  1. Marja Pertovaara1,2,
  2. Markku Korpela1,2
  1. 1Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland
  2. 2Department of Internal Medicine, University of Tampere, Medical School, Tampere, Finland
  1. Correspondence to Marja Pertovaara, Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, PO Box 2000, FIN-33521 Tampere, Finland; marja.pertovaara{at}uta.fi

https://doi.org/10.1136/ard.2011.153098

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Primary Sjögren's syndrome (pSS) is characterised clinically by sicca symptoms of the eyes and mouth. However, a proportion of pSS patients also present with extraglandular symptoms, for which immunosuppressive treatments may be needed. An expert panel of the European League Against Rheumatism (EULAR) has very recently developed a EULAR Sjögren's syndrome disease activity index (ESSDAI) to evaluate these systemic symptoms of pSS.1 The index consists of 12 organ-specific domains, which are predominantly clinical; only 2 of them include haematological (cytopenias) or biological (clonal component, serum complement levels, serum IgG and cryoglobulins) findings.1

    β2 Microglobulin is a low-molecular weight (11.8 kDa) polypeptide protein, which is one of the major histocompatibility class I molecules on the cell surfaces of all nucleated cells and is produced in particular by lymphocytes. We have previously reported that serum β …

    View Full Text